IDEMIA
A world first, remote smartphone-based passenger biometric registration gives passengers a smoother and contactless experience from ID registration until they board. Passenger faces - a genuine Open Sesame throughout the airport - are recorded at home on Mona, Lyon Airport’s smartphone app. Having registered in advance, passengers can put their travel documents away as they pass unhindered through the airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005759/en/
Passenger registration is secured by a biometric match between their smartphone-based face and scans of their ID document and boarding card. This totally accurate and reliable identity management system that IDEMIA has perfected lets passengers speed through all identity control points.
RESA’s latest automatic and biometric compact gate dubbed Major eGate , which caters for disabled people too, comes with an integrated camera so that passengers can pass through to the security restricted area and then board their plane based merely on facial recognition.
IDEMIA’s system is universal, secure and works on all airline systems thanks to RESA’s IATA-certified CUPPS system. This will be available at Lyon Airport for Transavia and TAP flights to Portugal.
While this new service is subject to formal CNIL1 approval, to date CNIL has recommended it to safeguard passenger data and rights.
IDEMIA Executive VP Identity and Public Safety Philippe Barreau said: “As biometric security solutions expert, we are thrilled to deliver a world first alongside our customers Vinci Airports and Lyon Airport and our partner RESA. This trial harnesses contactless biometric technology that gives users an unrivaled airport experience without letting up one jot on security. This bears out our capacity to constantly innovate to safeguard passenger trust and help pave the way for even smoother and more secure future travel .”
RESA CEO Renaud Willard said: “Current covid restrictions forced us to rethink how to take care of passengers and their interactions with airport security staff and equipment. The biometric trial underway at Lyon Airport was made possible by French industrial collaboration, whereby hi-tech saved the day despite the current pandemic and economic crisis. We have shown here that passengers can pass through airport checks fully contactless and without handing over paper documents while shoring up security to boot.”
Vinci Airports France & Americas Area Director Valérie Vesque-Jeancard said: “We are thrilled to launch MONA today, a world first, at a time when airports need game-changing innovations so they can give passengers an even safer, more enjoyable and personalized experience. I warmly congratulate all staff involved including IDEMIA and RESA people, who managed to overcome tough restrictions these last few months and deliver a great trial in barely a year.”
IDEMIA provides both rapid and safe passenger flow solutions to countless airports around the world and manages 30-plus government border control programs. In 2017, IDEMIA installed a facial recognition-based biometric ID control system in Terminal 4 of Singapore’s Changi Airport, from baggage check-in right through to aircraft boarding, including going airside and border crossing. The Company has regularly conducted facial recognition technology trials to make boarding smoother.
RESA’s expertise lies in introducing biometric technology to authenticate airport security staff, who need to connect to airport IT systems. RESA is currently engaged in introducing such technology on top of existing passenger airport systems. Previously, the firm has conducted several pilot tests including in Singapore and Paris airports.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About RESA
Backed by 30 years of experience and 1,000-plus software programs installed in 62 countries, RESA is one of the world’s top airport and airline systems developers.
The firm is an innovative Vendée-based small business that develops, sells and maintains a broad range of integrated software covering all airport system needs, including passenger check-in and boarding, baggage tracing and reconciliation, passenger tracking, automatic gates, self-service kiosks and biometrics, flight management, resource allocation, billing, statistics, business intelligence and messaging.
__________________________________
1
France’s national authority responsible for data privacy
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005759/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
